TU-7710 is under clinical development by TiumBio and currently in Phase I for Hemophilia. According to GlobalData, Phase I drugs for Hemophilia have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TU-7710’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NBP-604 is under development for the treatment of hemophilia. It is a recombinant long-acting activated Factor VII (FVIIa) fusion protein which is administetred through intravenous route..
TiumBio is a drug discovery company. The company’s pipeline products include chemical entity based drugs such as NCE401, NCE403, NCE406 and new biopharmaceuticals such as NBP604, NBP611 and NBP. It develops therapies for the treatment of idiopathic pulmonary fibrosis, endometriosis, uterine fibroids, prostate cancer, type 2 diabetes mellitus, hemophilia and rare diseases. TiumBio is headquartered in Seongnam-si, Gyeonggi-do, Korea
For a complete picture of TU-7710’s drug-specific PTSR and LoA scores, buy the report here.